These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 29968152)

  • 1. The Future of IL-1 Targeting in Kidney Disease.
    Afsar B; Covic A; Ortiz A; Afsar RE; Kanbay M
    Drugs; 2018 Jul; 78(11):1073-1083. PubMed ID: 29968152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
    Landmann EC; Walker UA
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating inflammation by blocking interleukin-1 in humans.
    Dinarello CA; van der Meer JW
    Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
    Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
    Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cryopyrin-associated periodic syndromes].
    Quartier P; Rodrigues F; Georgin-Lavialle S
    Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.
    Dinarello CA; Simon A; van der Meer JW
    Nat Rev Drug Discov; 2012 Aug; 11(8):633-52. PubMed ID: 22850787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CAPS treatment].
    Jiménez Treviño S; Ramos Polo E
    Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of interleukin-1 inhibitors in the management of gout.
    Tran TH; Pham JT; Shafeeq H; Manigault KR; Arya V
    Pharmacotherapy; 2013 Jul; 33(7):744-53. PubMed ID: 23553601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Interleukin-1 in Inflammatory and Malignant Human Skin Diseases and the Rationale for Targeting Interleukin-1 Alpha.
    Bou-Dargham MJ; Khamis ZI; Cognetta AB; Sang QA
    Med Res Rev; 2017 Jan; 37(1):180-216. PubMed ID: 27604144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].
    Lipsker D; Lenormand C
    Ann Dermatol Venereol; 2012 Jun; 139(6-7):459-67. PubMed ID: 22721478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryopyrin-associated periodic syndrome in early childhood can be successfully treated with interleukin-1 blockades.
    Eskola V; Pohjankoski H; Kröger L; Aalto K; Latva K; Korppi M
    Acta Paediatr; 2018 Apr; 107(4):577-580. PubMed ID: 29331074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rilonacept in the treatment of chronic inflammatory disorders.
    McDermott MF
    Drugs Today (Barc); 2009 Jun; 45(6):423-30. PubMed ID: 19649332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
    Church LD; McDermott MF
    Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
    Arnold DD; Yalamanoglu A; Boyman O
    Front Immunol; 2022; 13():888392. PubMed ID: 35874710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update in interleukin-1 inhibition].
    de Boysson H
    Rev Med Interne; 2012 Apr; 33(4):235-7. PubMed ID: 22360831
    [No Abstract]   [Full Text] [Related]  

  • 17. Rilonacept and canakinumab.
    Dubois EA; Rissmann R; Cohen AF
    Br J Clin Pharmacol; 2011 May; 71(5):639-41. PubMed ID: 21375570
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens.
    Kuemmerle-Deschner JB; Wittkowski H; Tyrrell PN; Koetter I; Lohse P; Ummenhofer K; Reess F; Hansmann S; Koitschev A; Deuter C; Bialkowski A; Foell D; Benseler SM
    Arthritis Res Ther; 2013; 15(3):R64. PubMed ID: 23718630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inflammasome and IL-1β: implications for the treatment of inflammatory diseases.
    Satoh T; Otsuka A; Contassot E; French LE
    Immunotherapy; 2015; 7(3):243-54. PubMed ID: 25804477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canakinumab.
    Dhimolea E
    MAbs; 2010; 2(1):3-13. PubMed ID: 20065636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.